Cover Image
市場調查報告書

Insulin Detemir的中國市場

Investigation Report on China Insulin Detemir Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 332308
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Insulin Detemir的中國市場 Investigation Report on China Insulin Detemir Market, 2010-2019
出版日期: 2015年06月04日 內容資訊: 英文 20 Pages
簡介

Insulin Detemir,由Novo Nordisk所製造的新世代長效型溶解胰島素注射液類同物,2005年在美國市場上市,2014年寫下20億美元的銷售量記錄。Insulin Detemir,2009年打入中國市場以來其銷售量急速擴大,2010年不到300萬人民幣的銷售量到2014年已達6800萬人民幣的規模。

本報告提供中國的Insulin Detemir市場規模與今後預測,提供您主要製藥公司及劑型別市場佔有率,銷售價格等資訊。

第1章 Insulin Detemir的相關概念

  • 適應
  • 全球市場的發展

第2章 中國Insulin Detemir的市場簡介

  • Insulin Detemir的專利及核準情況
  • 主要製藥公司
  • 市場規模

第3章 中國Insulin Detemir的銷售額

  • 整體銷售額
  • 各地區的銷售額

第4章 中國Insulin Detemir的銷售量

  • 整體銷售量
  • 各地區的銷售數

第5章 中國Insulin Detemir的主要製藥公司市場佔有率調查

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第6章 按中國的Insulin Detemir的劑型的市場規模調查

  • 劑型別市場佔有率:以銷售額為準
  • 劑型別市場佔有率:以銷售量為準

第7章 中國醫院的Insulin Detemir的標準價格

第8章 中國市場中Insulin Detemir的主要製藥公司

第9章 中國Insulin Detemir的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1506201

As economy develops and living standards improve, Chinese people's dietary pattern changes with heat, protein and fat coming from animals instead of vegetables, resulting in excess heat. Besides, people's ignorance of diabetes and the drop in physical activities lead to obesity. Other factors like the ageing population also play a role in the rapid increase of diabetes incidence in China.

Ever since insulin determir came into being, it has brought hope to patients with diabetes and has played an important role in diabetes treatment. With the advances in diabetes studies, the appearance of insulin analogue again cast new light on diabetes treatment. Insulin analogues include short-acting insulin analogues, long-acting insulin analogues and premixed insulin analogues, among which long-acting insulin analogues consist of insulin glargine and insulin determir.

Insulin Detemir, a new long-acting soluble (avoiding the common side effects of non-solvent insulin) human insulin analogue, was made by Novo Nordisk through energetic engineering. It came into the American market in 2005 and brought in sales revenue of USD 2 billion around the world in 2014.

According to CRI's market survey, insulin detemir develops fast after entering China in 2009, annual sales rising from less than CNY 3 million in 2010 to CNY 68 million in 2014 and CAGR during this period reaching up to 135%. Currently, insulin detemir market in China is monopolized by Novo Nordisk. The price range of 300 IU 3 ML insulin determir (one injection per package) in Chinese sample hospitals is CNY 193-205/package and there is little difference between citites.

The market size of insulin detemir in China is expected to keep growing in the next few years.

Readers can get at least the following information through this report:

  • market share of manufacturers of insulin detemir in Chinese market
  • price of insulin detemir in Chinese market
  • major manufacturers of insulin detemir in China
  • share of different dosage forms of insulin detemir in Chinese market
  • market outlook of insulin detemir in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-diabetic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Insulin Detemir

  • 1.1. Indication
  • 1.2. Developments in Global Market

2. Market Profile of Insulin Detemir in China

  • 2.1. Patent and Approval Status of Insulin Detemir in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Value of Insulin Detemir in China, 2010-2014

  • 3.1. Overall Sales Value
  • 3.2. Sales Value by Regions

4. Survey on Sales Volume of Insulin Detemir in China, 2010-2014

  • 4.1. Overall Sales Volume
  • 4.2. Sales Volume by Regions

5. Survey on Market Share of Major Manufacturers of Insulin Detemir in China, 2010-2014

  • 5.1. Market Share by Sales Value
  • 5.2. Market Share by Sales Volume

6. Survey on Market Size of Dosage Forms of Insulin Detemir in China, 2010-2014

  • 6.1. Market Share of Different Dosage Forms by Sales Value
  • 6.2. Market Share of Different Dosage Forms by Sales Volume

7. Reference Price of Insulin Detemir in Chinese Hospitals in 2013

8. Major Manufacturers of Insulin Detemir in Chinese Market, 2010-2014

9. Market Outlook of Insulin Detemir in China, 2014-2018

  • 9.1. Forecast of Market Size
  • 9.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Insulin Detemir in China
  • Chart Sales Status of Insulin Detemir in China, 2010-2014
  • Chart Sales Value of Insulin Detemir in China, 2010-2014
  • Chart Sales Value of Insulin Detemir in Some Regions in China, 2010-2014
  • Chart Sales Volume of Insulin Detemir in China, 2010-2014
  • Chart Sales Volume of Insulin Detemir in Some Regions in China, 2010-2014
  • Chart Sales Value and Market Share of Insulin Detemir Made by Novo Nordisk (Denmark) in China, 2010-20114
  • Chart Sales Value and Market Share of Insulin Detemir Made by Novo Nordisk (the US) in China, 2010-20114
  • Chart Sales Value and Market Share of Insulin Detemir Injection in China, 2010-2014
  • Chart Price of Insulin Detemir Made by Novo Nordisk (Denmark) in Some Regions in China
Back to Top